KOL Identification at Scale: Why Machine Learning Outperforms Business Rules

Every pharma company identifies Key Opinion Leaders. And almost every pharma company does it the same way: a set of business rules based on publication counts, clinical trial participation, and congress presentations, applied manually by medical affairs teams. This approach worked when the scientific landscape was simpler. It does not work when you need to identify and segment KOLs across 23 countries, multiple therapeutic areas, and rapidly evolving research frontiers.

The Limitations of Business Rules

Business rule-based KOL identification has three fundamental limitations. First, it relies on lagging indicators. By the time an emerging researcher has enough publications and congress presentations to trigger your business rules, they have likely already been identified by competitors. Second, it cannot capture influence patterns. Publication counts tell you who is producing research, but they do not tell you who is influencing clinical practice. Third, it does not scale. Applying manual business rules across 23 countries, each with different scientific landscapes and clinical practice patterns, requires significant human effort and inevitably produces inconsistent results.

The Machine Learning Approach

Machine learning-based KOL identification addresses all three limitations. Instead of counting publications, ML models analyze the relationships between researchers – who cites whom, who collaborates with whom, who speaks at the same congresses. This reveals influence networks that are invisible to business rule approaches.

ML models also incorporate real-world data that business rules ignore: prescribing patterns, referral networks, social media influence, and patient advocacy involvement. By combining these diverse data sources, the model can identify KOLs who are not just publishing research but actually influencing clinical practice.

One specialist consultancy implemented this approach with Infocepts, building a fully automated ML/AI solution using both supervised and unsupervised learning techniques. The supervised model was trained on historically validated KOL classifications, while the unsupervised model identified emerging clusters of influence that had not been previously recognized.

The Results

The ML approach achieved 85 percent or higher accuracy across all 23 countries – significantly better than the business rule approach, which had been declining in accuracy as the scientific landscape evolved. The automated system saved $170,000 annually in manual effort and, critically, enabled continuous model refresh. As new publications, congress data, and prescribing patterns became available, the model automatically updated its KOL rankings.

This continuous learning capability is perhaps the most important advantage. In a rapidly evolving scientific landscape – think cell and gene therapy, precision oncology, or immunology – the KOLs who matter today may be different from the ones who mattered two years ago. A static business rule cannot adapt to this pace of change. A machine learning model can.

Implementation Considerations

Organizations transitioning from business rules to ML-based KOL identification should consider three factors. First, data quality matters enormously. The model is only as good as the data it learns from. Investing in data curation and governance is essential. Second, explainability is critical for medical affairs adoption. MSLs need to understand why the model identifies someone as a KOL, not just that it does. Build explainability into the model design from the beginning. Third, start with a pilot in one therapeutic area and one geography before scaling. This allows you to validate the model’s accuracy against known KOL classifications and build organizational confidence.

The shift from business rules to machine learning for KOL identification is not a marginal improvement. It is a step-change in capability that enables pharma companies to identify influence faster, segment more precisely, and adapt continuously to an evolving scientific landscape.